9 Papers
60 Citations
Wei Liu is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Mutant & Cellular differentiation. The author has an hindex of 5, co-authored 9 publications. Previous affiliations of Wei Liu include Agios Pharmaceuticals & Pfizer.
Chat about Author
Papers
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle,Janeta Popovici-Muller,Nicolaos Palaskas,Sevin Turcan,Christian Grommes,Carl Campos,Jennifer Tsoi,Owen Clark,Barbara Oldrini,Evangelia Komisopoulou,Kaiko Kunii,Alicia Pedraza,Stefanie Schalm,Lee Silverman,Alexandra Miller,Fang Wang,Hua Yang,Yue Chen,Andrew Kernytsky,Marc K. Rosenblum,Wei Liu,Scott A. Biller,Shinsan M. Su,Cameron Brennan,Timothy A. Chan,Thomas G. Graeber,Katharine E. Yen,Ingo K. Mellinghoff,Ingo K. Mellinghoff +28 more
TL;DR: The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy, and isocitrate dehydrogenase 1 (IDH1), which is mutated in multiple human cancers, is examined.
1.1K
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
826
PAK4 inhibition improves PD-1 blockade immunotherapy
Gabriel Abril-Rodriguez,Davis Y. Torrejon,Wei Liu,Jesse M. Zaretsky,Theodore S. Nowicki,Jennifer Tsoi,Cristina Puig-Saus,Ignacio Baselga-Carretero,Egmidio Medina,Michael J. Quist,Alejandro J. Garcia,William Senapedis,Erkan Baloglu,Anusha Kalbasi,Gardenia Cheung-Lau,Beata Berent-Maoz,Begoña Comin-Anduix,Siwen Hu-Lieskovan,Cun-Yu Wang,Catherine S. Grasso,Antoni Ribas +20 more
- 01 Jan 2020
TL;DR: It is shown that p21-activated kinase 4 (PAK4) is enriched in non-responding tumor biopsies with low T cell and dendritic cell infiltration and a lack of response to PD-1 blockade, which could be reversed with PAK4 inhibition.
131
A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers
TL;DR: The identification of novel mediators of cellular resistance to neratinib could lead to the identification of new or neoadjuvant drug targets and their use as patient or treatment selection biomarkers could make the application of anti-ErbB therapeutics more clinically effective.
38
A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments
Attila A. Seyhan,Usha Varadarajan,Sung Choe,Yan Liu,John McGraw,Matthew Woods,Stuart Murray,Amy Eckert,Wei Liu,Terence E. Ryan +9 more
TL;DR: These findings support a paclitaxel and neratinib phase III clinical trial in breast cancer patients and identify a diverse set of genes whose depletion selectively impaired or enhanced the viability of SKBR-3 cells in the presence of Neratinib.